The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|December 11, 2014
Society for Clinical Research Sites Welcomes Clinical Ink as New Global Impact Partner
SCRS announced a two-year collaboration with Clinical Ink
Advertisement
“Clinical Ink’s relationship with SCRS illustrates their commitment to strengthening site partnerships and accelerating collaboration amongst industry stakeholders,” comments Christine Pierre, SCRS President. “Working together with this leading organization is a significant strategic development for SCRS, and will add considerable momentum to our Global Impact Partnership program. SCRS is proud to welcome Clinical Ink to our community.”
“This partnership reinforces our commitment to sites and dedication to making clinical research easier for sites, sponsors, subjects and regulators,” said Ed Seguine, CEO, Clinical Ink. “Clinical Ink was co-founded by a clinical investigator who understood the challenges of clinical research from 20+ years of experience. Through new collaborations as an SCRS GIP, we look forward to gaining insights that will help guide the continued evolution of SureSource as a primary tool for sites.”
As a Global Impact Partner (GIP), Clinical Ink will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
.
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
3
Where AI Governance in Clinical Development Falls Short
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5